An iron-based metalloprotein, Hemoglobin is found within the RBCs (red blood cells) of the human body. The primary role of Hemoglobin is to carry oxygen to the entire body from the lungs. Count of RBCs or the level of hemoglobin in blood is determined by the means of hemoglobin test. These tests are utilized broadly by doctors and physicians to identify any therapeutic disorder in the patient. Generally, people undertake the hemoglobin test owing to factors like poor health, fatigue, or unexplained weight loss. If the test results show a low hemoglobin concentration in the blood, it signifies higher likelihood of patients being anemic.
The global hemoglobin testing market is expected to witness boost during forecast period mainly due to the rising incidence of chronic disorders like diabetes and anemia. In addition, enhancing health infrastructure, growing alertness about blood-related disorders, escalating per capita spending on health care, and growing population base of elderly people are other factors expected to spur the market expansion in the near future. Also, swift technological innovations will back the introduction of cutting-edge testing kits having the ability to provide accurate results in a short time period along with satisfactory compensation of hemoglobin testing included under several health insurance policies will drive the market growth to great extent. Moreover, growing number of approvals by FDA for new hemoglobin tests as well as analyzers will drive market expansion. To cite, Danaher subsidiary, HemoCue, in February 2019, declared of obtaining consent for its point of care testing product from the US FDA.
The global hemoglobin testing devices market can be segregated based on technology, product, end-use, and region. the market, by product, is categorized into consumables and equipment. The equipment segment is further divided into laboratory-based analyzers and point of care. The point of care is again sub-divided into handheld, portable, and bench-top. The market, by technology, is categorized into immunoassay, chromatography, and spectrophotometry. The market, by end-use, is classified into clinics, hospitals, home care settings, laboratories, and blood banks.
Geographically, North America will lead the global hemoglobin testing devices market during the forecast period on account of the rising count of research studies to discover new therapeutic applications. Further, the rising R&D activities in relation to hemoglobin analyzers with the objective of offering better and effective outcomes will drive the regional market growth. Also, Asia Pacific anticipated to witness swift growth over the coming period on account of growing spending in research & development by government and local medical device firms in budding economies like China, India, and Japan.
The prominent players in the global hemoglobin testing devices market comprise Bio-Rad Laboratories, Abbott, EKF Diagnostics, Danaher, Siemens Healthineers, F. Hoffmann-La Roche, Alere, Thermo Fisher Scientific, ARKRAY, ACON Laboratories, Daiichi Biotech, Bayer Medical Care, Epinex Diagnostics, DiaSys Diagnostic Systems, Erba Diagnostics, and others.
